** U.S.-listed shares of Switzerland-based drug developer Oculis Holding CR5.F, OCS.O rise 6.8% to $18.75 premarket
** Co says its drug, OCS-05, met the main goal of safety in a mid-stage trial testing it in patients with acute optic neuritis, an inflammatory condition that causes sudden vision loss
** Says the drug also improved patients' visual function during the trial
** Up to last close, stock up 66.3% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。